Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2008-10-23 Director's Dealing
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Change of Director`s Interest Notice - Options 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in a director's relevant interests in securities, including the number of securities held before and after the change, nature of the interest, and dates. The document is a formal notification of a director's personal share transactions, specifically the grant of options under an employee option plan. The content matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is 3256 characters, which is consistent with a detailed notice rather than a brief announcement or a full report. Therefore, the correct classification is DIRS (Director's Dealing).
2008-10-23 English
Appendix 3B - Option Grants to Employees 11 pages ?Kb
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B' and is described as a 'New issue announcement, application for quotation of additional securities and agreement.' It details the issuance of unlisted employee options, including exercise prices, expiry dates, vesting schedules, and the number of securities issued. The document references ASX (Australian Securities Exchange) rules and codes, indicating it is a formal announcement related to securities issuance. There is no financial performance data, management discussion, or audit information. The content is focused on the issuance of new securities and their terms, which aligns with announcements about share issues or capital changes. Therefore, this document fits the category of Share Issue/Capital Change (SHA). The document length is substantial (15,000 characters), indicating it is not a brief notice but a detailed announcement of a capital change.
2008-10-23 English
CEO Presentation to 2008 AGM 33 pages ?Kb
AGM Information Classification · 95% confidence The document is titled 'Annual General Meeting 23 October 2008' and contains detailed information about the company's products, clinical trials, regulatory status, commercial strategy, and milestones. It includes extensive content typical of presentations or materials shared during an Annual General Meeting (AGM). There is no indication that this is a full annual report (10-K) or a financial report; rather, it appears to be an AGM presentation or information pack. The length (15,000 characters) and detailed content support this classification. Therefore, the document fits best under AGM Information (AGM-R).
2008-10-22 English
Chairman`s Address to AGM 2 pages ?Kb
AGM Information Classification · 95% confidence The document is titled 'PHARMAXIS LTD 2008 Annual General Meeting Chairman’s Address' and contains a speech by the Chairman addressing shareholders at the AGM. It discusses company progress, market conditions, clinical trials, board changes, and thanks shareholders. There is no detailed financial data or comprehensive report content, but rather a presentation or speech given at the AGM. The length is 4448 characters, which is consistent with a presentation or address rather than a full annual report. Therefore, this document fits the category of AGM Information (AGM-R).
2008-10-22 English
Pharmaxis Aridol Approved for Sale in Switzerland 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a media release dated 20 October 2008 from Pharmaxis Ltd announcing the approval of their product Aridol for sale in Switzerland by the Swiss regulatory agency Swissmedic. It describes the product, its market approval status in various countries, distribution arrangements, and some background on the company and product. There are no financial statements, no detailed financial performance data, no regulatory filings or certifications, no voting results, no management or board changes, no earnings data, and no merger or acquisition information. The document is a corporate announcement about product approval and market entry, typical of a press release or media release. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. Given the content and nature, the best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2008-10-19 English
Appendix 4C - Quarterly Cash Flow 5 pages ?Kb
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly report for entities admitted on the basis of commitments' and contains detailed financial data including consolidated statement of cash flows, cash flow related to operating, investing, and financing activities, reconciliation of cash, and compliance statements. It covers a specific quarter ending 30 September 2008. The content is substantive financial data for a period shorter than a full fiscal year, consistent with a quarterly report. The document is over 7,000 characters, so it is not a mere announcement or certification. The presence of detailed financial statements and cash flow analysis aligns with the definition of an Interim / Quarterly Report (IR). Q1 2009
2008-10-14 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.